

## GLOBAL ADVOCACY

The Stop TB Partnership unites over 1500 partners and leads global advocacy in the fight to End TB by 2030.

Stop TB mobilized millions of people through our annual World TB Day campaign and other events, achieved major reductions in the prices of TB diagnostics and medicines, and united and empowered people affected by TB, civil society, and communities by giving them a voice, platform, visibility and capacity.

The Global Plan to End TB 2016-2020 drives our work to put TB higher on the political agenda, mobilize resources, and create a paradigm shift in the global TB movement.

## STRENGTHENING COMMUNITIES

People affected by TB and the grassroots organizations must be at the heart of all efforts to end TB.

Stop TB has the following areas of work: **Challenge Facility for Civil Society (CFCS)** grant programme; ensuring TB programmes are centred on **human rights, gender sensitive interventions, and stigma reduction**; increasing access of **key and vulnerable populations** to quality TB services; and investing in **strengthening community systems** and engagement in global, regional and national platforms.



OP  
TB Partnership



HELP BRING  
THE TB EPIDEMIC  
TO AN END



UNITE TO  
END TB →

TB is the world's leading  
infectious disease killer

Stop TB Partnership  
hosted by  
UNOPS

The  
ST



## WHO WE ARE

The Stop TB Partnership is a unique international body, which is a part of the United Nations family, that aligns all actors over the world to End TB.

The Stop TB Partnership ensures a voice for the TB community at the highest levels.

Various programmes identify and fund innovative approaches to find, treat and cure people affected by TB.

The Stop TB Partnership plays a key role in procuring TB drugs and diagnostics, including the roll-out of new tools across the world. Its market shaping strategy also helps to reduce prices, improve forecasting and prevent stock-outs for drugs.

Stop TB Partnership



### TB REACH

TB REACH is a multi-lateral funding mechanism which provides grants to partners for testing innovative strategies and technologies aimed at increasing the number of people diagnosed and treated for tuberculosis (TB), decreasing the time to appropriate treatment and improving treatment success.

TB REACH combines fast-track, results-based financing and rigorous, external monitoring and evaluation (M&E) to produce results, so national governments and/or other donor agencies can scale up successful approaches and maximize their own investments.

### GLOBAL DRUG FACILITY

The Global Drug Facility (GDF) is a one-stop, bundled procurement and supply mechanism for quality assured TB health products aimed at facilitating world-wide, equitable access to TB medicines and diagnostics across both public and private sectors.

Global Drug Facility combines strategic procurement and innovative logistics solutions, management and coordination of market activities for the full portfolio of TB medicines and diagnostics, technical assistance and capacity building for TB programmes in better pharmaceutical management practices, and accelerated uptake of new TB medicines, regimens, and diagnostics.

### PARTNERING WITH THE PRIVATE SECTOR

In order to End TB by 2030 and reach the Sustainable Development Goals, it is imperative that the Stop TB Partnership meaningfully collaborate with the private sector to solve for critical, systemic barriers in the TB space. More importantly, Stop TB needs to harness both the public and private sector expertise and investment to work with local businesses and innovators to catalyze economic growth and sustainability in the developing countries.



## KEY ACHIEVEMENTS

### GDF (Global Drug Facility)



Between 2001 and 2015

#### DELIVERED TB DRUGS

25.8 million adult TB treatments  
1.5 million pediatric TB treatments  
187, 853 treatments for drug resistant TB

#### PROCURED TB DIAGNOSTICS

worth US\$ 131 million for more than 76 countries

#### ENSURED

Bedaquiline, delamanid and new pediatric formulations are available  
A stable and competitive supplier base

### STRENGTHENING COMMUNITIES



Between 2007 and 2016

#### AWARDED (CHALLENGE FACILITY)

131 grants through 7 rounds  
strengthening grass roots community systems

#### DEVELOPED

TB gender assessment tool and  
9 key populations miniguides

#### STRENGTHENED NETWORKS

and people centered approaches through the engagement of people affected by TB  
in 42 countries.

### TB REACH



Between 2010 and 2016

#### PROVIDED

142 grants in 46 countries  
for US\$ 95 million

#### OUR TB REACH GRANTEES DIAGNOSED AND TREATED

Over 2 million people with TB, saving 600, 000 lives in the most underserved populations while working in close collaboration with National TB Programmes.

#### TB REACH REPLENISHED

for nearly CAD 100 million for 2016-2020

### ADVOCACY

(High Level)



LAUNCHED THE GLOBAL PLAN TO END TB and the 90-(90)-90 TB targets

#### SECURED

Heads of States commitment to increase TB financing and achieving the 90 90 90 targets

#### REVIEW ON ANTIMICROBIAL RESISTANCE

includes MDR-TB as a lead priority

#### SUPPORTED

the 4th Global Fund Replenishment (\$12 billion) and increase its TB allocation from 16 to 18%

www.stoptb.org



### STOP TB PARTNERSHIP STRUCTURES

SECRETARIAT	<b>BOARD COMPOSITION</b>	<ul style="list-style-type: none"> <li>Countries Affected by TB</li> <li>Communities Affected by TB</li> <li>Developing Country Non-Governmental Organization</li> <li>Developed Country Non-Governmental Organization</li> <li>Donors</li> <li>Foundations</li> <li>Multi-Lateral Organizations</li> <li>Private Sector</li> <li>Technical Agencies</li> <li>Working Groups</li> <li>Open Seats</li> </ul>
	<b>WORKING GROUPS</b>	<ul style="list-style-type: none"> <li>Global Drug-resistant TB Initiative (GDI)</li> <li>Global Laboratory Initiative (GLI)</li> <li>End TB Transmission initiative (ETT)</li> <li>Public-Private Mix Subgroup (PPM)</li> <li>Childhood TB Subgroup</li> <li>TB/HIV Working Groups</li> <li>New Diagnostics Working Group (NDWG)</li> <li>Working Group on New Drugs (WGND)</li> <li>Working Group on New Vaccines (WGNV)</li> </ul>
	<b>GLOBAL TB CAUCUS</b>	
	<b>NATIONAL PLATFORMS</b>	National platforms in 27 countries
	<b>GLOBAL COALITION OF TB ACTIVISTS (GCTA)</b>	6 regions
	<b>PEOPLE AFFECTED BY TB</b>	1 region

### DONORS IN 2016

The Stop TB Partnership's work is made possible only through the support of the Partnership's many funders and partners. We appreciate their trust and gratefully acknowledge their support.

Bill & Melinda Gates Foundation  
DNA Genotek Inc.  
Eli Lilly & Co.  
Global Affairs Canada  
The Global Fund to Fight AIDS, Tuberculosis and Malaria  
Kochon Foundation  
UNITAID  
United Nations Foundation  
USAID  
US Centers for Disease Control and Prevention

